Elof Eriksson | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Elof Eriksson | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Prof. Dr Elof Eriksson, Harvard Medical school, United States

Dr. Elof Eriksson, MD, PhD, is an esteemed plastic surgeon and researcher, born in Sweden. He earned his MD in 1969 and a PhD in Physiology in 1972 from the University of Göteborg. After relocating to the United States in 1973, he trained in general surgery at the University of Chicago and plastic surgery at the Medical College of Virginia. He has held key academic and clinical roles, notably as Chief of Plastic Surgery at Brigham and Women’s Hospital and Children’s Hospital in Boston. In 1996, he was named the first Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School. Renowned for his pioneering work in wound healing, Dr. Eriksson also established several specialized programs, including face transplantation. After stepping down as Chief in 2016, he became Professor Emeritus. Dr. Eriksson’s legacy includes over 200 publications, 50 patents, and numerous prestigious awards in surgery and biomedical research.

Publication Profile

scopus

Education

Dr. Eriksson began his medical and scientific journey in Sweden, where he earned an MD in 1969 and a PhD in Physiology in 1972 from the University of Göteborg. His dual degree underscores his deep commitment to both clinical excellence and biomedical research. Following his move to the United States in 1973, he pursued further training in surgery, completing his general surgery residency at the University of Chicago. He then specialized in plastic surgery, finishing his residency at the Medical College of Virginia. This strong educational foundation prepared Dr. Eriksson for a distinguished international career that bridged academic medicine, clinical innovation, and research leadership. His training in both physiology and surgery uniquely positioned him to develop translational research programs in wound healing and plastic surgery that have had a global impact. His dedication to academic medicine led to his appointment as the first Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School.

Experience

Dr. Elof Eriksson has over four decades of clinical, academic, and research experience. After his U.S.-based surgical training, he returned to Sweden to serve as an attending plastic surgeon at the University of Göteborg for three years. In 1982, he became the Director of the Burn Center at Southern Illinois University, where he focused on acute care and wound management. In 1986, he was recruited to Brigham and Women’s Hospital and Children’s Hospital in Boston as Chief of Plastic Surgery, a role he held until 2016. Under his leadership, the division expanded from 1 to 19 faculty members, and he initiated groundbreaking programs in wound care, microsurgery, breast reconstruction, and face transplantation. In 1996, he was named the Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School. He also served on various national boards and hospital committees, reflecting his leadership in clinical governance and academic surgery.

Awards and Honors

Dr. Eriksson’s groundbreaking contributions in plastic surgery and wound healing have earned him numerous awards and honors. He was the recipient of the Harvard Plastic Surgery Teaching Award, recognizing his excellence in academic mentorship. His lifetime achievements were celebrated with the Boswick Lifetime Achievement Award from the Symposium on Advanced Wound Care and the Lifetime Achievement Award from the Wound Healing Society. For his pioneering research, he was also honored by the American Association of Plastic Surgeons and the Plastic Surgery Foundation. Beyond accolades, he served in leadership roles including President of the Wound Healing Society and the Wound Healing Foundation, and a board member of the American Board of Plastic Surgery. His extensive service was also recognized through his appointment to the Board of Trustees at Dartmouth Hitchcock Medical Center. These honors reflect both his clinical excellence and his significant impact on translational and surgical sciences.

Research Focus

Dr. Elof Eriksson’s research focuses on wound healing, integrating basic science, translational research, and clinical innovation. He has explored advanced methodologies ranging from gene transfer techniques to strategies that regulate the wound microenvironment in response to acute trauma. His laboratory has led numerous federally funded studies, including substantial support from the National Institutes of Health (NIH) and the U.S. Department of Defense, aimed at improving wound care for trauma patients and military personnel. Dr. Eriksson’s research has significantly advanced our understanding of tissue regeneration, inflammation control, and post-injury cellular behavior. He has published over 200 peer-reviewed articles and is the first author of more than 50 patents, many of which have led to innovative therapies in clinical use. His work bridges the gap between lab research and surgical application, particularly in developing new treatments for complex wounds, burn injuries, and reconstructive surgery.

Publication Top Notes

  • “Gene transfer strategies for wound healing optimization”

  • “Modulation of wound microenvironment after acute trauma”

  • “Topical application of growth factors in burn wounds”

  • “Strategies for improving graft integration in skin reconstruction”

  • “The role of inflammation in chronic wound healing”

  • “Clinical outcomes of face transplantation procedures”

  • “Advancements in vascularized composite allotransplantation”

  • “Application of tissue-engineered scaffolds in wound care”

  • “NIH-funded translational research in acute wound management”

  • “Gene expression profiling of wound healing phases”

  • “Controlled delivery systems for wound therapeutics”

  • “Collagen remodeling and scar minimization techniques”

  • “Defense-sponsored innovations in trauma wound therapy”

  • “Multidisciplinary approaches to facial reconstruction”

  • “Clinical trials in bioengineered skin substitutes”

Salma Abdelnasser | Life Sciences | Best Researcher Award

Dr. Salma Abdelnasser | Life Sciences | Best Researcher Award

Researcher at National Research Centre, Egypt

Dr. Salma Abdelnasser is an accomplished researcher with a PhD in Microbiology from Ain Shams University, Cairo, Egypt. Her expertise lies in the production and characterization of novel marine bacterial exopolysaccharides and their therapeutic potential, particularly in the context of cancer treatment. She has extensive technical skills, including the isolation and purification of bacterial strains, RNA isolation, real-time PCR, and advanced data analysis. Dr. Abdelnasser has held various positions at the National Research Center (NRC) in Cairo, ranging from Research Specialist to her current role as a Researcher. She has led significant research projects, including studies on the role of miRNAs and exopolysaccharides in hepatocellular carcinoma, and the purification and characterization of marine bacterial exopolysaccharides. Her research has been published in reputable journals, reflecting her contributions to the field of microbial biotechnology and cancer therapeutics.

Professional Profiles:

📚 Education:

Dr. Salma Abdelnasser is an accomplished academic with a Doctor of Philosophy in Science (PhD) specializing in Microbiology from the Faculty of Science at Ain Shams University in Cairo, Egypt. Her doctoral research focused on the “Production of Novel Marine Bacterial Exopolysaccharides: Their Effect on Immunological Response and Apoptotic Pathways for Hepatocellular Carcinoma.” This thesis explored innovative approaches in microbiology, examining how marine bacterial exopolysaccharides can influence immune responses and apoptotic mechanisms in the context of liver cancer.

Professional Experience:

Dr. Salma Abdelnasser has held several key positions in the Microbial Biotechnology Department, Genetic Engineering & Biotechnology Division, at the National Research Center (NRC) in Cairo, Egypt. Since July 2018, she has been serving as a Researcher, where she continues to contribute to significant advancements in microbial biotechnology. Prior to this role, she was an Assistant Researcher from January 2016 to July 2018, demonstrating her growing expertise and dedication to her field. From August 2013 to January 2016, Dr. Abdelnasser worked as a Research Assistant, building her foundation in research methodologies and techniques. Her career at the NRC began as a Research Specialist, a position she held from January 2007 to August 2013. Throughout her tenure at the NRC, Dr. Abdelnasser has consistently shown a commitment to advancing genetic engineering and biotechnology.

Skills:

Dr. Salma Abdelnasser possesses a robust set of technical skills relevant to her field of expertise. She is proficient in the isolation and purification of bacterial strains from marine sediment through serial dilution and streak plate methods. Additionally, she has extensive experience in the production, isolation, and purification of bacterial exopolysaccharides (EPSs). Dr. Abdelnasser is skilled in identifying EPS-producing bacterial strains with high rates of cell death through 16S rRNA gene sequencing. She can assess the in vitro cytotoxicity of partially purified EPSs extracted from marine bacterial strains using in vitro cytotoxic assays. To confirm the proposed chemical structures of EPSs, she analyzes their infrared (IR) spectra, mass spectra, and high-performance liquid chromatography (HPLC) data. Dr. Abdelnasser is adept at isolating RNA and employing real-time PCR to assess the apoptotic activity of promising EPSs, followed by statistical analysis of the PCR data. Furthermore, she studies the pro-apoptotic effects of promising EPSs using the Human Apoptosis Antibody Array-Membrane (43 targets) ab134001 Kit (abcam® England) and is proficient in analyzing data from antibody arrays. These skills underscore Dr. Abdelnasser’s extensive expertise and capabilities in microbiological research and its applications.

Research:

Dr. Salma Abdelnasser has led several impactful research projects as a Principal Investigator. One of her notable projects is titled “Investigating the Role of miRNAs on Apoptotic and Angiogenic Pathways in Hepatocellular Carcinoma Cells Treated with Bacillus sonorensis Exopolysaccharide (EPS-1),” which runs from 2022 to 2024 and is funded by the National Research Centre, Giza, Egypt (grant number: 13060123). This study aims to explore the potential synergistic effects of miRNA and EPS-1 on pro-apoptotic and anti-angiogenic genes. Hybrid anticancer drugs are emerging as promising therapeutic options that can effectively address the limitations of conventional anticancer drugs. This project seeks to demonstrate the positive role of combining miRNA and EPS-1 in modulating key genes involved in the development, progression, and metastasis of hepatocellular carcinoma (HCC). Given that the expression of microRNAs is often altered in cancer cells, and that exopolysaccharides (EPSs) are gaining attention as a novel source for cancer treatment, this research holds significant potential for advancing cancer therapeutics.

 

📚Publications :

Publication: “Preventive potential of Bacillus sonorensis exopolysaccharide upon hepatocellular carcinoma and quantitation of tumor suppressor protein p53”

Authors: Abdelnasser, S.M., Ahmed, Y.M.

Journal: European Journal of Cancer Prevention

Year: 2022

Volume: 31(6), pp. 513–522

Citations: 0

Publication: “Human apoptosis antibody array-membranes studying the apoptotic effect of marine bacterial exopolysaccharides in HepG2 cells”

Authors: Abdelnasser, S., Yahya, S.M., Mohamed, W., Mahmoud, M., Asker, M.S.

Journal: Journal of Cancer Research and Therapeutics

Year: 2021

Volume: 17(1), pp. 38–45

Citations: 2

Publication: “Newly isolated marine bacterial exopolysaccharides enhance antitumor activity in HepG2 cells via affecting key apoptotic factors and activating toll-like receptors”

Authors: Yahya, S.M.M., Abdelnasser, S.M., Hamed, A.R., El Sayed, O.H., Asker, M.S.

Journal: Molecular Biology Reports

Year: 2019

Volume: 46(6), pp. 6231–6241

Citations: 17

Publication: “Antitumor exopolysaccharides derived from novel marine Bacillus: Isolation, characterization aspect and biological activity”

Authors: Abdelnasser, S.M., Yahya, S.M.M., Mohamed, W.F., Mahmoud, M.G., Gadallah, M.A.

Journal: Asian Pacific Journal of Cancer Prevention

Year: 2017

Volume: 18(7), pp. 1847–1854

Citations: 33

Publication: “Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells”

Authors: Yahya, S.M.M., Hamed, A.R., Emara, M., Abd-Ellatef, G.E.F., Abdelnasser, S.M.

Journal: Tumor Biology

Year: 2016

Volume: 37(5), pp. 5925–5932

Citations: 8